Neoadjuant PARP inhibitor treatment shrinks tumors in BRCA-positive breast cancer patients

All 13 newly diagnosed breast cancer patients with BRCA mutations had their tumors shrink significantly when treated with a PARP inhibitor ahead of frontline presurgical chemotherapy in a pilot study at The University of Texas MD Anderson Cancer Center. Results of the study (abstract 153PD) will be presented Saturday at a breast cancer poster discussion …

Neoadjuant PARP inhibitor treatment shrinks tumors in BRCA-positive breast cancer patients Read More »